Pulmonx (LUNG) Q4 2025 earnings review
Growth Engine Stalls, But Restructuring Drives Margin Breakout
Pulmonx's growth narrative has officially hit a wall, but a hard pivot to financial discipline is softening the blow. U.S. revenue reversed sharply in Q4, contracting 11% YoY and dragging total worldwide sales down 5%. This complete breakdown of the U.S. commercial strategy contrasts sharply with the 'second-half acceleration' prior management promised earlier in 2025. However, the returning leadership team delivered on their Q3 promise to prioritize profitability: operating expenses dropped 11% and gross margin surged to an impressive 78%. FY26 guidance projects essentially flat revenue ($90-92M), signaling that the company has abandoned its 'growth-at-all-costs' model to focus on cash preservation, securing a new debt facility, and finding a sustainable baseline.
🐂 Bull Case
Gross margin accelerated to 78% in Q4 from 74% a year ago. Combined with an 11% reduction in operating expenses, Adjusted EBITDA loss narrowed significantly to $5.5M.
The company refinanced its debt, securing up to $60M in a 5-year interest-only facility. With FY26 cash burn guided to just $23M and $69.8M currently on the balance sheet, survival risk is minimized.
🐻 Bear Case
The U.S. business is reversing. After growing 16% in 24Q4, growth decelerated all year until breaking into an 11% contraction in 25Q4. Past investments have failed to yield returns.
FY26 revenue guidance of $90-92M implies essentially flat growth year-over-year. The previous long-term target of 20%+ annual growth has been entirely abandoned.
⚖️ Verdict: 🔴
Bearish. While management deserves credit for executing a rapid, effective cost restructuring and expanding margins, the core product's U.S. adoption is actively shrinking. Without top-line growth, the valuation multiple will remain compressed.
Key Themes
U.S. Revenue is Reversing
The most alarming metric is the U.S. revenue contraction of 11% YoY ($14.1M). Throughout early 2025, prior management blamed the U.S. slowdown on 'capacity constraints' and 'longer conversion cycles,' promising an acceleration in H2. The Q4 data directly contradicts that positive narrative, proving that the underlying issues were demand-driven or structural rather than temporary workflow delays.
Cost Restructuring and Margin Acceleration
Under the new leadership of CEO Glen French, financial discipline is accelerating. Operating expenses fell 11% YoY to $27.4M in Q4. More impressively, gross margins spiked to 78% (vs 74% a year ago). Management successfully executed a 'line-by-line review' of spending, shedding underperforming commercial initiatives to protect the balance sheet.
International Growth is Decelerating
The international segment, which carried the company in the first half of 2025, is now decelerating rapidly. Growth dropped to 8% YoY in Q4, down from 15% in Q3 and 39% in Q1. While this partially reflects the normalization of aggressive distributor stocking (especially in China) seen earlier in the year, it leaves the company without a growth engine to offset U.S. weakness.
Failure of the 'Acquire, Test, Treat' Tech Strategy
In Q1/Q2, management heavily promoted specific tech innovations like the LungTraX Detect AI platform and targeted Direct-to-Patient (DTP) advertising as the catalysts that would 'bypass referral bottlenecks.' The resulting 11% U.S. sales decline in Q4 strongly suggests these initiatives failed to generate sufficient ROI and have likely been scaled back under the new restructuring plan.
Securing the Balance Sheet
Management successfully refinanced existing debt to secure up to $60M in committed capital under a new 5-year interest-only credit facility extending to 2031. Combined with $69.8M in cash and marketable securities, the company has bought itself the necessary time to weather this transition period without dilutive equity raises.
Macroeconomic and FX Headwinds
Foreign exchange dynamics continue to pressure reported results. Worldwide revenue declined 5% on a reported basis, but 7% on a constant currency basis in Q4. International revenue was up 8% reported but only 2% on a constant currency basis, showing that underlying ex-U.S. volume growth has nearly flatlined.
AeriSeal Pipeline Optionality
Despite commercial struggles with the core Zephyr valve, the clinical pipeline remains a long-term driver. The company continues to advance the AeriSeal CONVERT II trial (targeting collateral ventilation patients), which management previously estimated could expand the addressable market by 20%. Protecting clinical investments during the OpEx cuts was a key priority.
Other KPIs
Accelerating improvement. This is a significant narrowing from the -$7.5 million loss in 24Q4 and -$8.2 million in 25Q3, proving that the aggressive cost-cutting measures implemented in late 2025 are successfully driving the company toward cash-flow breakeven despite top-line contraction.
Down approximately $32 million from $101.5 million at the end of 2024. The cash burn trajectory is expected to improve, with FY26 guidance projecting roughly $23 million in cash usage, validating the effectiveness of the recent restructuring.
Guidance
Stable to slightly Decelerating. The midpoint of $91 million represents less than 1% growth compared to FY25 actuals ($90.5M). This marks a dramatic reset from the company's historical 20%+ growth targets and acknowledges the reality of a stalled U.S. market.
Stable. Represents a slight improvement over the FY25 full-year average of 74%, though below the 78% achieved in Q4. This indicates management expects to maintain the pricing and manufacturing efficiencies realized late in the year.
Decelerating. A clear reduction from the $120.8 million spent in FY25. Inclusive of $21 million in stock-based compensation, the cash OpEx is guided to approximately $92-94 million, tightly aligning with expected revenue to minimize cash burn.
Accelerating improvement in cash preservation. This implies ending FY26 with nearly $47 million in cash, comfortably supporting operations assuming no further drawdowns on the new $60M credit facility.
Key Questions
U.S. Commercial Baseline
With U.S. revenue contracting 11% in Q4, do you believe we have found the absolute bottom in terms of account utilization, or does the FY26 guidance imply further U.S. degradation offset by modest international growth?
Cuts to Innovation Initiatives
To achieve the 11% reduction in operating expenses, which specific commercial programs—such as LungTraX, Therapy Awareness Specialists, or DTP marketing—were scaled back or eliminated?
AeriSeal Development Timeline
Given the strict reduction in FY26 operating expenses ($113-$115M), will there be any delay in the CONVERT II trial enrollment or the expected 2026/2027 commercialization timeline for AeriSeal?
Gross Margin Sustainability
Gross margin hit an impressive 78% in Q4, but FY26 guidance calls for ~75%. What dynamics (mix, volume leverage, or price) are driving the conservative 75% target compared to the Q4 exit rate?